Sickle cell trait refers to the presence of one sickle cell gene and one normal gene, while sickle cell anemia occurs when a person inherits two sickle cell genes. Sickle cell disease leads to abnormal hemoglobin formation causing red blood cells to become rigid and crescent-shaped, which can result in various complications. Individuals with sickle cell trait typically do not exhibit symptoms and lead normal lives, whereas those with sickle cell anemia experience painful crises and various health challenges due to the obstruction of blood flow and related anemia.

Individuals with sickle cell trait generally have a low risk of complications; however, under extreme conditions such as high altitudes, extreme dehydration, or intense physical exertion, they may experience health issues. In contrast, those with sickle cell anemia face numerous risks including severe pain crises, increased susceptibility to infections, stroke, chronic organ damage, and reduced life expectancy. Genetic counseling is recommended for carriers of the sickle cell trait who are planning to have children.

People with sickle cell trait typically do not show symptoms, while individuals with sickle cell anemia may present with severe symptoms such as recurrent episodes of pain (crises), fatigue, paleness, shortness of breath, and an increased risk of infections. Symptoms can vary greatly in severity and frequency, with some individuals experiencing frequent crises leading to hospitalization. Chronic complications may include acute chest syndrome, organ dysfunction, and leg ulcers, significantly impacting quality of life.

Sickle cell trait (SCT) and sickle cell anemia (SCA) are hereditary blood disorders caused by mutations in the HBB gene on chromosome 11, which encodes for the beta-globin subunit of hemoglobin. SCT occurs when an individual inherits one sickle cell gene from a parent and one normal gene, while SCA occurs when an individual inherits two sickle cell genes. This mutation leads to the production of abnormal hemoglobin, known as hemoglobin S, which can distort red blood cells into a sickle or crescent shape, particularly under low oxygen conditions. The prevalence of these conditions is notably higher among individuals of African, Mediterranean, Middle Eastern, and Indian descent due to historical selective advantages against malaria conferred by the trait.

Sickle cell trait and sickle cell anemia are diagnosed through blood tests that evaluate hemoglobin types present in the blood. Newborn screening programs in many countries routinely check for sickle cell disease, allowing early identification and management. Genetic testing can confirm the presence of the sickle cell gene, providing essential information for family planning and management.

Management strategies for sickle cell anemia focus on alleviating symptoms, preventing complications, and improving quality of life. Treatment options may include pain management with analgesics, hydroxyurea to increase fetal hemoglobin levels and reduce sickling, blood transfusions to alleviate severe anemia, and preventive antibiotics in young children to reduce infection risk. Bone marrow or stem cell transplantation can potentially cure SCA but is typically limited to severe cases due to availability issues and the need for a suitable donor.

While sickle cell trait cannot be prevented, individuals with this condition should be aware of their status, particularly before conception, to understand the implications for their offspring. Sickle cell anemia management focuses on preventing crises through regular medical care, vaccination, and prophylactic antibiotics. Lifestyle modifications, including staying well-hydrated and avoiding extreme temperatures, can help reduce the frequency of pain episodes in affected individuals.